Additionally, we summarize the current evidence regarding the efficacy and safety of GH and IGF-1 as therapeutic targets for managing obesity, including in pharmacological interventions and hormone replacement therapy. Here, IGF1 is linked to obesity due to melanocortin 4 receptor deficiency.